All Glaukos Articles
-
367News BriefsGlaukos Receives Permanent J-code for Epioxa
New J-code for EpioxaTM, J2789, set to become effective July 1, 2026 April 15, 2026 Glaukos Corporation (NYSE: GKOS) announced the U.S....
-
362News Briefs
Glaukos Expands Portfolio With Commercial Launch of Epioxa
The first and only FDA-approved, incision-free, topical drug therapy for keratoconus March 19, 2026 Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and...
-
1.4KNews BriefsNew Next-Generation Visual Field Solution Available
A new wearable testing option
